Carolina Isiegas1, Jorge A Marinich-Madzarevich1, Miguel Marchena2, José M Ruiz1, María J Cano1, Pedro de la Villa2, Catalina Hernández-Sánchez3, Enrique J de la Rosa4, Flora de Pablo3. 1. ProRetina Therapeutics, S.L., Noain, Spain. 2. Department of System Biology, School of Medicine, Universidad de Alcalá de Henares, Madrid, Spain. 3. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Madrid, Spain 43D Lab, Development, Differentiation & Degeneration, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Cie. 4. 3D Lab, Development, Differentiation & Degeneration, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CIB/CSIC), Madrid, Spain.
Abstract
PURPOSE: The induction of proinsulin expression by transgenesis or intramuscular gene therapy has been shown previously to retard retinal degeneration in mouse and rat models of retinitis pigmentosa (RP), a group of inherited conditions that result in visual impairment. We investigated whether intraocular treatment with biodegradable poly (lactic-co-glycolic) acid microspheres (PLGA-MS) loaded with proinsulin has cellular and functional neuroprotective effects in the retina. METHODS: Experiments were performed using the Pde6brd10 mouse model of RP. Methionylated human recombinant proinsulin (hPI) was formulated in PLGA-MS, which were administered by intravitreal injection on postnatal days (P) 14 to 15. Retinal neuroprotection was assessed at P25 by electroretinography, and by evaluating outer nuclear layer (ONL) cellular preservation. The attenuation of photoreceptor cell death by hPI was determined by TUNEL assay in cultured P22 retinas, as well as Akt phosphorylation by immunoblotting. RESULTS: We successfully formulated hPI PLGA-MS to deliver the active molecule for several weeks in vitro. The amplitude of b-cone and mixed b-waves in electroretinographic recording was significantly higher in eyes injected with hPI-PLGA-MS compared to control eyes. Treatment with hPI-PLGA-MS attenuated photoreceptor cell loss, as revealed by comparing ONL thickness and the number of cell rows in this layer in treated versus untreated retinas. Finally, hPI prevented photoreceptor cell death and increased AktThr308 phosphorylation in organotypic cultured retinas. CONCLUSIONS: Retinal degeneration in the rd10 mouse was slowed by a single intravitreal injection of hPI-PLGA-MS. Human recombinant proinsulin elicited a rapid and effective neuroprotective effect when administered in biodegradable microspheres, which may constitute a future potentially feasible delivery method for proinsulin-based treatment of RP.
PURPOSE: The induction of proinsulin expression by transgenesis or intramuscular gene therapy has been shown previously to retard retinal degeneration in mouse and rat models of retinitis pigmentosa (RP), a group of inherited conditions that result in visual impairment. We investigated whether intraocular treatment with biodegradable poly (lactic-co-glycolic) acid microspheres (PLGA-MS) loaded with proinsulin has cellular and functional neuroprotective effects in the retina. METHODS: Experiments were performed using the Pde6brd10 mouse model of RP. Methionylated human recombinant proinsulin (hPI) was formulated in PLGA-MS, which were administered by intravitreal injection on postnatal days (P) 14 to 15. Retinal neuroprotection was assessed at P25 by electroretinography, and by evaluating outer nuclear layer (ONL) cellular preservation. The attenuation of photoreceptor cell death by hPI was determined by TUNEL assay in cultured P22 retinas, as well as Akt phosphorylation by immunoblotting. RESULTS: We successfully formulated hPI PLGA-MS to deliver the active molecule for several weeks in vitro. The amplitude of b-cone and mixed b-waves in electroretinographic recording was significantly higher in eyes injected with hPI-PLGA-MS compared to control eyes. Treatment with hPI-PLGA-MS attenuated photoreceptor cell loss, as revealed by comparing ONL thickness and the number of cell rows in this layer in treated versus untreated retinas. Finally, hPI prevented photoreceptor cell death and increased AktThr308 phosphorylation in organotypic cultured retinas. CONCLUSIONS:Retinal degeneration in the rd10mouse was slowed by a single intravitreal injection of hPI-PLGA-MS. Human recombinant proinsulin elicited a rapid and effective neuroprotective effect when administered in biodegradable microspheres, which may constitute a future potentially feasible delivery method for proinsulin-based treatment of RP.
Authors: Alberto Hernández-Pinto; Federica Polato; Preeti Subramanian; Andrés de la Rocha-Muñoz; Susan Vitale; Enrique J de la Rosa; S Patricia Becerra Journal: Exp Eye Res Date: 2019-04-10 Impact factor: 3.467
Authors: Alonso Sánchez-Cruz; María D Hernández-Fuentes; Cayetana Murillo-Gómez; Enrique J de la Rosa; Catalina Hernández-Sánchez Journal: Cells Date: 2022-05-12 Impact factor: 7.666
Authors: Clayton P Santiago; Casey J Keuthan; Sanford L Boye; Shannon E Boye; Aisha A Imam; John D Ash Journal: Mol Ther Date: 2018-07-19 Impact factor: 11.454
Authors: Alonso Sánchez-Cruz; Beatriz Villarejo-Zori; Miguel Marchena; Josefa Zaldivar-Díez; Valle Palomo; Carmen Gil; Ignacio Lizasoain; Pedro de la Villa; Ana Martínez; Enrique J de la Rosa; Catalina Hernández-Sánchez Journal: Mol Neurodegener Date: 2018-04-16 Impact factor: 14.195
Authors: Alonso Sánchez-Cruz; Alberto Hernández-Pinto; Concepción Lillo; Carolina Isiegas; Miguel Marchena; Ignacio Lizasoain; Fátima Bosch; Pedro de la Villa; Catalina Hernández-Sánchez; Enrique J de la Rosa Journal: Cell Death Dis Date: 2022-04-20 Impact factor: 9.685
Authors: Paul Yang; Rachel Lockard; Hope Titus; Jordan Hiblar; Kyle Weller; Dahlia Wafai; Richard G Weleber; Robert M Duvoisin; Catherine W Morgans; Mark E Pennesi Journal: Invest Ophthalmol Vis Sci Date: 2020-08-03 Impact factor: 4.799